fbpx

REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search
News

Therapy-Resistant Basal Cell Carcinoma Patients React Positively to New Treatment

Carcinoma
Immunotherapy found to be effective for the treatment of basal cell carcinoma skin cancer

Basal cell carcinoma (BCC) is a type of cancer that most often develops on areas of skin exposed to the sun, such as the face, and is the most common form of skin cancer. Traditionally, BCC is treated with surgery to remove the malignant tissue. When the type of the tumor does not allow for surgery, doctors often employ biological drugs. However, the latter can cause severe side effects.

Highly effective, and with fewer side effects compared to other BCC immunotherapy drugs, Cemiplimab offers new hope for patients. A PD-1 inhibitor, Cemiplimab blocks the activity of certain checkpoint proteins that tend to be present on the surface of cells and signal immune cells not to attack.

According to a recent study by Sheba Medical Center, Cemiplimab is highly effective in treating BCC, as the tumor shrunk significantly in 30 percent of participants, while 60 percent experienced some reduction in size or a halt in development. These patients either did not react to standard biological treatments or experienced severe side effects.

Related
News Mar 26.
West Bank and Gaza Medical Professionals Attend a Milestone Sheba Oncology Conference
Highlighting the latest in cancer care, with a particular focus on pediatrics, the Recent Advances in Cancer Care (REACT) 2023 event was attended by over…
Read More
Isenia’s Battle
Isenia’s Battle with Alveolar Sarcoma
At 17, Isenia, a native of Semey, Kazakhstan, noticed a lump on her leg the size of a small apple. Initially, Isenia and her family…
Read More
Colon and Rectal Cancer
News Mar 14.
Sheba Study Indicates Readily-Available Drugs May Prevent Metastasis in Colon and Rectal Cancer Patients
Favorable responses to the treatment were noted by Prof. Shamgar Ben-Eliyahu, a neuroscientist specializing in psychoneuroimmunology (PNI) at TAU’s Sagol School of Neuroscience and School…
Read More